Critical analysis of the Affordable Care Act's impact on the U.S. healthcare and insurance markets, highlighting debates on single payer and market roles.

The American Heart Association endorses single-pill combination therapy to improve hypertension management and reduce cardiovascular risks among U.S. adults.

CMS is set to lower costs for Wegovy and Zepbound weight loss drugs, potentially improving coverage and access for Medicare, Medicaid, and commercial insurance patients amid varied state and employer restrictions.

In 2025, U.S. health insurers face surging medical expenses driven by rising prescription drug costs, particularly from GLP-1 weight-loss medications, prompting coverage reevaluation.

Eli Lilly cuts prices for cash buyers of Zepbound, impacting pharmaceutical pricing and payer coverage dynamics.

U.S. Senate set to vote on extending enhanced Obamacare subsidies as GOP senators propose alternatives focusing on tax deductions, PBM transparency, and Health Savings Accounts to address rising healthcare premiums.

Explore how over 30 U.S. states have enacted drug price transparency laws requiring manufacturers, health plans, and PBMs to report pricing data, aiding state efforts to analyze and regulate high prescription drug costs.

The FDA appoints Tracy Beth Høeg as the new director of CDER, marking the fifth leadership change this year, impacting drug regulation and insurance sectors.

Healthcare Brew spotlights important healthcare insurance and policy analyses from leading publications, covering health insurance challenges, Medicaid cuts, journalistic trust, and pharmaceutical industry shifts.

Medicare's Inflation Reduction Act negotiations cut prices for 15 top prescription drugs by 44%, reducing out-of-pocket costs and impacting Medicare Part D and Part B markets.